Methylation of PITX2 DNA feasible in prostate biopsies

December 13, 2016

(HealthDay)—For patients with prostate cancer (PCa), methylation of the paired-like homeodomain transcription factor 2 (PITX2) gene is feasible for individualized risk assessment in prostate core biopsies before surgery, according to a study published online Dec. 8 in the Journal of Molecular Diagnostics.

Barbara Uhl, from the University Hospital Bonn in Germany, and colleagues examined whether PITX2 methylation is feasible for individualized in prostate core biopsies before surgery. PITX2 was measured using a quantitative, methylation-specific real-time (PCR) in three cohorts: matched samples of neoplastic and non-neoplastic tissue from 24 PCa patients; a cohort of 300 patients with PCa after radical prostatectomy; and core biopsy specimens from 32 PCa patients and 31 patients with benign prostatic disease.

The researchers found that in patients with PCa, PITX2 methylation discriminated between neoplastic and non-neoplastic tissue (P < 0.001). PITX2 methylation correlated with clinicopathologic parameters in the second cohort, and PITX2 hypermethylation predicted an elevated risk of biochemical recurrence. Overall, 720 of 753 were applicable for analysis; PITX2 methylation was increased in tumor-positive biopsies and correlated with the International Society of Urological Pathology grade groups.

"This study indicates that the PITX2 methylation assay is feasible in prostate biopsies and might add valuable prognostic information for risk assessment in a presurgical diagnostic setting," the authors write.

Explore further: DNA methylation biomarker for prostate cancer shows promise for accurately determining patient risk

More information: Full Text (subscription or payment may be required)

Related Stories

DNA methylation biomarker for prostate cancer shows promise for accurately determining patient risk

December 8, 2016
Prostate-specific antigen (PSA) and other biomarkers are essential tools for diagnosing and monitoring prostate cancer. However, biomarkers to selectively identify patients with high risk of recurrence, those who might benefit ...

Age, obesity affect gene expression in symptomatic BPH

September 26, 2015
(HealthDay)—Age and obesity affect gene regulation in men with symptomatic benign prostatic hyperplasia, according to a study published in the October issue of The Journal of Urology.

Methylation of gene panel may help predict breast CA survival

November 29, 2016
(HealthDay)—Methylation of a gene panel is a strong predictor of survival outcomes in metastatic breast cancer (MBC), according to a study published online Nov. 21 in the Journal of Clinical Oncology.

New accurate epigenetic test could eliminate unnecessary repeat biopsies for prostate cancer

July 21, 2014
More than one million prostate biopsies are performed each year in the U.S. alone, including many repeat biopsies for fear of cancer missed. Therefore there is a need to develop diagnostic tests that will help avoid unnecessary ...

MRI feasible for predicting prostate CA in unselected sample

July 18, 2016
(HealthDay)—Prostate multiparametric magnetic resonance imaging (MRI) is feasible for predicting prostate cancer in an unselected sample of the general population, according to a study published in the August issue of The ...

Study affirms value of epigenetic test for markers of prostate cancer

May 28, 2014
A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many—if ...

Recommended for you

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

Researcher fighting breast cancer with light therapy

October 17, 2018
When treatment is working for a patient who is fighting cancer, the light at the end of the tunnel is easier to see.

New method uses just a drop of blood to monitor lung cancer treatment

October 17, 2018
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.